The model is not enough. Alphabet spent twelve years proving it.

For a decade CRISPR has been framed almost entirely as a pair of molecular scissors. Cut here, paste there, cure the disease. That framing is useful, but it's also getting in the way of seeing what the technology is quietly becoming.

The more interesting work happening right now treats Cas proteins less like a tool and more like a programmable interface to the cell. Base editors and prime editors rewrite letters without a double-strand break. CRISPRi and CRISPRa turn genes down and up like a mixing board. Cas13 targets RNA, opening a reversible layer on top of the genome.

And then there are the diagnostics. SHERLOCK, DETECTR, and the newer amplification-free readouts have quietly turned Cas enzymes into some of the most sensitive detection reagents we have. A pandemic-era assay can now sit on a paper strip.

The next decade of CRISPR probably won't be defined by a single celebrity cure. It will be defined by how ordinary this machinery becomes — in diagnostics, in manufacturing, in the day-to-day language of building with cells.